Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease

Fig. 3

PBT434 prevents toxin induced cell loss and improves motor performance. a 6-OHDA injection resulted in the loss of 65% of the SNpc neurons compared with unlesioned control animals. PBT434 administration commencing 3 days following intoxication and significantly preserved neuron numbers compared with vehicle (p < 0.001, One-way ANOVA, Tukey Post Hoc). The number of neurons in an unlesioned mouse is 6124 ± 23. L-DOPA did not protect neurons against 6-OHDA toxicity. b Mice treated with PBT434 (30 mg/kg/day, N = 11 (P < 0.05) or L-DOPA (15 mg/kg, P < 0.001, One-way ANOVA, Tukey Post Hoc) showed significantly fewer rotations than vehicle treated mice. c PBT434 (30 mg/kg/day for twenty days) administered 24 h following intoxication with MPTP resulted in significantly reduced SNpc neuronal loss (*** P < 0.001, One-way ANOVA, Tukey Post Hoc). PBT434-met 30 mg/kg/day (PBT434 without the metal binding site) does not protect against MPTP. d PBT434 treatment resulted in improvement in motor performance in the Pole test (* P < 0.05, One-way ANOVA, Tukey Post Hoc). UL = unlesioned, VEH = standard suspension vehicle without compound, PBT434-met = analogue of PBT434 without the metal binding

Back to article page